On May 9, Phanes announced that it had reached a clinical supply agreement with Roche.To study PhanesWorld's First DLL3/CD47 Bispecific Antibody PT217AndRoche's PD-L1 Inhibitor AtezolizumabIn treatmentSmall Cell Lung Cancer (SCLC)、Large Cell Neuroendocrine Carcinoma of the Lung (LCNEC)AndExtrapulmonary Neuroendocrine Carcinomas (EP-NECs)In patientsCombination Therapy。

PT217 was granted Orphan Drug Designation by the FDA in 2022 for the treatment of small cell lung cancer and has recently received Fast Track Designation from the FDA., for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease progression after receiving platinum-based chemotherapy., regardless of whether they have received combination therapy with immune checkpoint inhibitors.

Phanes' PT217 Multicenter Phase I Clinical Trial in the United StatesSKYBRIDGE Study (NCT05652686)Patients are currently being recruited for this Phase I clinical trial, which is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of PT217 in patients with advanced or refractory cancers expressing DLL3.

Rita Laeufle, MD, Chief Medical Officer of Phanes, stated:"We are delighted toCollaborate with Roche on new treatment regimens for small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), and extrapulmonary neuroendocrine carcinomas (EP-NECs).DLL3 is highly expressed in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), and extrapulmonary neuroendocrine carcinomas (EP-NECs), making it an important target for the treatment of these cancers. We believe that the mechanism of PT217 complements atezolizumab, and this combination therapy holds promise to improve patient outcomes. This collaboration marks another milestone for Phanes in realizing its vision of developing innovative approaches to cancer treatment."